Argos Therapeutics, Inc. (NASDAQ:ARGS) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Argos Therapeutics, Inc. (NASDAQ:ARGS) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

Story continues below

(a)

On October 26, 2017, Argos Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The NASDAQ Stock Market LLC (“Nasdaq”) indicating that (i) the Company has not regained compliance with the minimum $50,000,000 market value of listed securities requirement for continued listing on The Nasdaq Global Market (the “MVLS Requirement”), and (ii) unless the Company requests a hearing before a Nasdaq Hearing Panel (“Panel”), trading of the Company’s common stock will be suspended at the opening of business on November 6, 2017.

Accordingly, the Company intends to request a hearing before a Panel at which it will request continued listing pending its return to compliance. The Company’s hearing request will stay the suspension of trading and delisting of the Company’s common stock pending the conclusion of the hearing process and the expiration of any additional extension period granted by the Panel. Consequently, the Company’s common stock will remain listed on The Nasdaq Global Market at least until the Panel renders a decision following the hearing.

As previously reported, on April 28, 2017, the Staff notified the Company that it had not been in compliance with the MVLS Requirement for 10 consecutive business days and indicated that the Company would have a compliance period of 180 calendar days, or until October 25, 2017, to regain compliance with the MVLS Requirement.

Also as previously reported, on May 2, 2017, the Staff notified the Company that, based on the closing bid price of the Company’s common stock for the 30 consecutive business days prior to May 2, 2017, the Company no longer satisfied the requirement for continued listing on The Nasdaq Global Market that the Company maintain a minimum bid price of $1.00 per share, and indicated that the Company has 180 calendar days, or until October 30, 2017, to regain compliance with the minimum bid price requirement for continued listing.

In addition, as previously reported, on May 9, 2017, the Staff notified the Company that it was not in compliance with the minimum $15,000,000 market value of publicly held shares requirement for continued listing on The Nasdaq Global Market, and that the Company has 180 calendar days, or until November 6, 2017, to regain compliance with the market value of publicly held shares requirement for continued listing.

In connection with the hearing, the Company may ask the Panel to transfer its listing to The Nasdaq Capital Market to a listing “exception.” In such an event, the applicable continued listing requirements would be a market value of publicly held shares of $1,000,000, which the Company currently meets, a $1.00 per share bid price and a market value of listed securities of $35,000,000 or, alternatively, $2,500,000 in stockholders’ equity. In the event the Panel were to grant a request to transfer to The Nasdaq Capital Market, the maximum extension period that could be granted would run through April 24, 2018.


About Argos Therapeutics, Inc. (NASDAQ:ARGS)

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

An ad to help with our costs